Swallowable Blood Detector Gets Class II Status
Published Date: 6/17/2026
Rule
Summary
The FDA is officially putting the ingestible gastrointestinal blood detection capsule into Class II, meaning it now has special safety rules but fewer hurdles than before. This change helps patients get access to this cool, innovative device faster and keeps it safe and effective. The new classification is effective June 17, 2026, and could save time and money for makers and users alike.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Easier pathway for future device makers
If you make medical devices, FDA’s De Novo classification of the ingestible gastrointestinal blood detection capsule means this device can serve as a predicate for future devices, allowing sponsors to use the less-burdensome 510(k) process instead of a De Novo or premarket approval pathway. This change is effective June 17, 2026, and the classification was applicable on February 24, 2023.
New safety and labeling requirements
The device is now Class II with specific special controls that require clinical performance testing (including comparison to endoscopy for detecting GI bleeding, capsule excretion/recovery, and all adverse events), many non-clinical tests (dimensional, performance, battery life, leak, bite, pH resistance, bioburden control, and blood detection), software validation, electrical/thermal/mechanical and electromagnetic testing, usability, biocompatibility, shelf-life demonstration, and detailed physician and patient labeling. These special controls are part of the codified rule effective June 17, 2026 (classification applicable February 24, 2023).
Premarket 510(k) submission required
Manufacturers of ingestible gastrointestinal blood detection capsules must submit a premarket notification under section 510(k); FDA has not exempted this device type under section 510(m). This premarket notification requirement applies as part of the Class II classification effective June 17, 2026 (classification applicable February 24, 2023).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12166 — Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
The FDA is officially putting radiology software that uses machine learning and has a set plan for updates into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new tech. It’s been effective since early 2023, so companies can expect fewer hoops to jump through without extra costs or delays.
2026-12167 — Andrew Jonathan Morgan: Final Debarment Order
Andrew Jonathan Morgan is officially banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime related to drug importation. He didn’t respond to the FDA’s notice, so the ban started on June 17, 2026, and he can apply to end it anytime. This means no drug imports from him for a while, keeping things safe and legal.
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
Previous / Next Documents
Previous: 2026-12149 — Equal Credit Opportunity (Regulation B); Special Purpose Credit Programs; Rescission
The Consumer Financial Protection Bureau is canceling a 2020 advisory opinion about special credit programs made by for-profit companies to help certain social groups. This change affects lenders and businesses using these programs, clarifying how the Equal Credit Opportunity rules apply. The cancellation takes effect on June 17, 2026, so affected parties should review their credit policies soon to avoid confusion or legal risks.
Next: 2026-12166 — Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
The FDA is officially putting radiology software that uses machine learning and has a set plan for updates into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new tech. It’s been effective since early 2023, so companies can expect fewer hoops to jump through without extra costs or delays.